ADC Landscape
Gilead
TROP2 · TNBC, HR+ breast, urothelial
ApprovedAntibody–Drug Conjugates
Target
TROP2
Payload
SN-38
Payload class
Topo-I inhibitor
Linker
Hydrolyzable (CL2A)
Indication
TNBC, HR+ breast, urothelial
Phase
Approved
Partner
— (acq. Immunomedics $21B)
Overview
First TROP2 ADC approved. Uniquely high DAR (~7.6) with a fast-hydrolyzing linker. Anchored Gilead's $21B Immunomedics buy — the deal that signaled big pharma's all-in on ADCs.
Technology
Gilead works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Roche / Genentech
HER2
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.